A Cyclooxygenase-2 Selective Inhibitor Worsens Respiratory Function and Enhances Mast Cell Activity in Ovalbumin-Sensitized Mice;Un inhibidor selectivo de la ciclooxigenasa-2 empeora la función respiratoria y fomenta la actividad de los mastocitos en ratones sensibilizados a la ovalbúmina

Archivos de Bronconeumologia

Volumn 45, Issue 4, 2009, Pages 162-167

  Torres, Rosa ^a,b,c   Pérez, Mónica ^a   Marco, Alberto ^a   Picado, César ^b,c   de Mora, Fernando ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Asthma; Cyclooxygenase 2; Hyperresponsiveness; Mast cell; Ovalbumin sensitized mouse; Rofecoxib

Indexed keywords

BRINASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; METHACHOLINE; OVALBUMIN; ROFECOXIB;

AIRWAY DYNAMICS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; BODY PLETHYSMOGRAPHY; BRONCHUS HYPERREACTIVITY; CELL ACTIVITY; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; EXPERIMENTAL MOUSE; EXPOSURE; FUNCTIONAL ASSESSMENT; MAST CELL; MOUSE; MUCOSA CELL; NONHUMAN; PROVOCATION TEST; RESPIRATORY FUNCTION; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY TRACT MUCOSA; SCORING SYSTEM; SENSITIZATION;

EID: 64049083098     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S1579-2129(09)71015-8     Document Type: Article

References (31)

1. Ito S., Okuda A., Shitaka E., and Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res. 41 (2001) 299-332
2. Hata A.N., and Breyer R.M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 103 (2004) 147-166
3. Mardini I.A., and Fitzgerald G.A. Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs. Mol Interv. 1 (2001) 30-38
4. Kowalski M.L., and Makowska J. Use of nonsteroidal anti-inflammatory drugs in patients with aspirin hypersensitivity : safety of cyclo-oxygenase-2 inhibitors. Treat Respir Med. 5 (2006) 399-406
5. Prieto A., De Barrio M., Martín E., Fernández-Bohórquez M., De Castro F.J., Ruiz F.J., et al. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance. J Allergy Clin Immunol. 119 (2007) 960-964
6. Matsuoka T., Hirata M., Tanaka H., Takahashi Y., Murata T., Kabashima K., et al. Prostaglandin D2 as a mediator of allergic asthma. Science. 287 (2000) 2013-2017
7. Melillo E., Woolley K.L., Manning P.J., Watson R.M., and O'Byrne P.M. Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med. 149 (1994) 1138-1141
8. Sestini P., Armetti L., Gambaro G., Pieroni M.G., Refini R.M., Sala A., et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTC4 excretion in aspirin-sensitive asthmatics. Am J Respir Crit Care Med. 153 (1996) 572-575
9. Gauvreau G.M., Watson R.M., and O'Byrne P.M. Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med. 159 (1999) 31-36
10. Edmunds A.T., Tooley M., and Godfrey S. The refractory period after exercise-induced asthma: its duration and relation to the severity of exercise. Am Rev Respir Dis. 117 (1978) 247-254
11. Manning P.J., Watson R.M., and O'Byrne P.M. Exercise-induced refractoriness in asthmatic subjects involves leukotriene and prostaglandin interdependent mechanisms. Am Rev Respir Dis. 148 (1993) 950-954
12. Picado C., Fernández-Morata J.C., Juan M., Roca-Ferrer J., Fuentes M., Xaubet A., et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med. 160 (1999) 291-296
13. Kowalski M.L., Pawliczak R., Wozniak J., Siuda K., Poniatowska M., Iwaszkiewicz J., et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med. 161 (2000) 391-398
14. Mullol J., Fernández-Morata J.C., Roca-Ferrer J., Pujols L., Xaubet A., Benítez P., et al. Cyclooxygenase-1 and-2 expression is abnormally regulated in human nasal polyps. J Allergy Clin Immunol. 109 (2002) 824-830
15. Chambers L.S., Black J.L., Ge Q., Carlin S.M., Au W.W., Poniris M., et al. PAR-2 activation, PGE2, and COX-2 in human asthmatic and nonasthmatic airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 285 (2003) L619-L627
16. Picado C., Bioque G., Roca-Ferrer J., Pujols L., Mullol J., Benítez P., et al. Nuclear factor-kappaB activity is down-regulated in nasal polyps from aspirin-sensitive asthmatics. Allergy. 58 (2003) 122-126
17. Pierzchalska M., Szabo Z., Sanak M., Soja J., and Szczeklik A. Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma. J Allergy Clin Immunol. 1111 (2003) 1041-1048
18. Torres R., Picado C., and De Mora F. Use of the mouse to unravel allergic asthma: a review of the pathogenesis of allergic asthma in mouse models and its similarity to the condition in humans. Arch Bronconeumol. 41 (2005) 141-152
19. Gavett S.H., Madison S.L., Chulada P.C., Scarborough P.E., Qu W., Boyle J.E., et al. Allergic lung responses are increased in prostaglandin H synthase-deficient mice. J Clin Invest. 104 (1999) 721-732
20. Peebles Jr. R.S., Dworski R., Collins R.D., Jarzecka K., Mitchell D.B., Graham B.S., et al. Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice. Am J Respir Crit Care Med. 162 (2000) 676-681
21. Peebles Jr. R.S., Hashimoto K., Morrow J.D., Dworski R., Collins R.D., Hashimoto Y., et al. Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice. Am J Respir Crit Care Med. 165 (2002) 1154-1160
22. Nakata J., Kondo M., Tamaoki J., Takemiya T., Nohara M., Yamagata K., et al. Augmentation of allergic inflammation in the airways of cyclooxygenase-2-deficient mice. Respirology. 10 (2005) 149-156
23. Bradding P., Walls A.F., and Holgate S.T. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol. 117 (2006) 1277-1284
24. Feng C., Beller E.M., Bagga S., and Boyce J. Human mast cells express multiple EP receptors for prostaglandin E2 that differentially modulate activation responses. Blood. 107 (2006) 3243-3250
25. Kay L.J., Wilfred W.Y., and Peachell P.T. Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br J Pharmacol. 147 (2006) 707-713
26. Kobayashi T., Miura T., Haba T., Sato M., Serizawa I., Nagai H., et al. An essential role of mast cells in the development of airway hyperresponsiveness in a murine asthma model. J Immunol. 164 (2000) 3855-3861
27. Hamelmann E., Schwarze J., Takeda K., Oshiba A., Larsen G.L., Irvin C.G., et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med. 156 (1997) 766-775
28. Lomask M. Further exploration of the Penh parameter. Exp Toxicol Pathol. 57 Suppl 2 (2006) 13-20
29. Beil W.J., and Pammer J. In situ detection of the mast cell proteases chymase and tryptase in human lung tissue using light and electron microscopy. Histochem Cell Biol. 116 (2001) 483-493
30. Zembowicz A., Mastalerz L., Setkowicz M., Radziszewski W., and Szczeklik A. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol. 139 (2003) 1577-1582
31. Mita H., Endoh S., Kudoh M., Kawagishi Y., Kobayashi M., Taniguchi M., et al. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy. 56 (2001) 1061-1067